Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Krystal Biotech Inc

Healthcare US KRYS

307.79USD
5.97(1.98%)

Last update at 2026-06-04T20:00:00Z

Day Range

298.93312.38
LowHigh

52 Week Range

93.95189.97
LowHigh

Fundamentals

  • Previous Close 301.82
  • Market Cap4540.79M
  • Volume264886
  • P/E Ratio72.94
  • Dividend Yield-%
  • EBITDA-50.61400M
  • Revenue TTM95.95M
  • Revenue Per Share TTM3.45
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM2.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -139.97500M -69.57000M -32.16700M -19.08800M -10.88900M
Minority interest - - - - -
Net income -139.97500M -69.57000M -32.16700M -19.08800M -10.88900M
Selling general administrative 77.73M 40.39M 15.06M 6.46M 4.16M
Selling and marketing expenses - - - - -
Gross profit - - - - 1.03M
Reconciled depreciation 4.05M 2.77M 1.85M 0.75M 0.14M
Ebit -145.19600M -68.27500M -32.99900M -22.08100M -11.91600M
Ebitda -110.92000M -65.30900M -31.14800M -21.33300M -11.77500M
Depreciation and amortization 34.28M 2.97M 1.85M 0.75M 0.14M
Non operating income net other - - - - -
Operating income -145.19600M -68.27500M -32.99900M -22.08100M -11.91600M
Other operating expenses 120.20M 68.28M 33.00M 22.08M 11.92M
Interest expense 5.22M 1.49M 0.83M 0.00000M 1.03M
Tax provision - - - - -
Interest income 5.22M 0.20M 0.83M 2.99M 1.03M
Net interest income 5.22M -1.29500M 0.83M 2.99M 1.03M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 19.78M 1.49M -0.83200M -2.99300M 2.05M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 1.03M
Total operating expenses 120.20M 68.28M 33.00M 22.08M 11.92M
Cost of revenue - - - - 0.00000M
Total other income expense net 5.22M -1.29500M 0.83M 2.99M 1.03M
Discontinued operations - - - - -
Net income from continuing ops -139.97500M -69.57000M -32.99900M -19.08800M -10.88900M
Net income applicable to common shares -139.97500M -69.57000M -32.16700M -19.08800M -10.88900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 818.36M 558.45M 626.29M 310.84M 209.02M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.71M 4.61M 4.17M 3.80M 2.19M
Total liab 39.71M 36.22M 32.72M 18.76M 6.11M
Total stockholder equity 778.64M 522.23M 593.58M 292.08M 202.91M
Deferred long term liab - - - - -
Other current liab 27.49M 23.30M 0.09M 0.03M 0.02M
Common stock - - - - -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -269.82700M -280.75900M -140.78400M -71.21400M -39.04700M
Other liab - - - - -
Good will - - - - -
Other assets - 0.32M 0.07M 4.91M 1.46M
Cash 358.33M 161.90M 341.25M 268.27M 187.51M
Cash and equivalents - - - - -
Total current liabilities 33.09M 28.85M 25.74M 15.45M 3.33M
Current deferred revenue 0.00000M - 16.21M 5.08M 2.10M
Net debt -350.23400M -152.96700M -333.22200M -256.72300M -184.25200M
Short term debt 1.47M 1.56M 1.04M 8.24M 0.48M
Short long term debt - - - - -
Short long term debt total 8.09M 8.93M 8.02M 11.55M 3.26M
Other stockholder equity 1047.83M 803.72M 734.52M 363.29M 241.95M
Property plant equipment - 169.73M 119.58M 30.88M 11.18M
Total current assets 587.91M 383.78M 442.27M 275.06M 195.88M
Long term investments 61.95M 4.62M 64.37M 0.00000M 0.50M
Net tangible assets - 522.23M 593.58M 292.08M 202.91M
Short term investments 173.85M 217.27M 96.85M 2.99M 6.17M
Net receivables 42.04M - - - -
Long term debt - - - - -
Inventory 6.99M - - - -
Accounts payable 4.13M 3.98M 8.40M 2.10M 0.72M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.64M -0.72800M -0.16300M 0.00600M 0.01000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - -140.78400M -71.21400M -39.04700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.26M 0.32M 0.07M 1.61M 1.46M
Deferred long term asset charges - - - - -
Non current assets total 230.45M 174.67M 184.03M 35.79M 13.14M
Capital lease obligations 8.09M 8.93M 8.02M 11.55M 3.26M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -114.08300M -158.43400M 3.66M 1.43M -10.32300M
Change to liabilities -1.25400M 0.71M 3.09M -1.01400M 0.11M
Total cashflows from investing activities -114.08300M -226.77000M -11.18100M -4.96800M -10.32300M
Net borrowings - - - - -
Total cash from financing activities 35.35M 347.69M 118.02M 107.53M 73.85M
Change to operating activities 4.07M 1.34M 0.14M -1.70600M 0.40M
Net income -139.97500M -69.57000M -32.16700M -19.08800M -10.88900M
Change in cash -179.34600M 72.98M 80.75M 83.84M 54.08M
Begin period cash flow 341.25M 268.27M 187.51M 103.67M 49.59M
End period cash flow 161.90M 341.25M 268.27M 187.51M 103.67M
Total cash from operating activities -100.56900M -47.93800M -26.08300M -18.71300M -9.44500M
Issuance of capital stock 36.00M 355.64M 118.02M 107.53M 73.85M
Depreciation 4.05M 2.77M 1.85M 0.75M 0.14M
Other cashflows from investing activities - - - 1.43M -8.08900M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - 355.64M 118.02M 107.53M 73.85M
Other cashflows from financing activities -0.64900M -7.96000M -11.18100M -4.96800M -10.32300M
Change to netincome 32.54M 16.81M 3.99M 1.31M 0.79M
Capital expenditures 52.98M 68.34M 14.84M 6.40M 2.23M
Change receivables - - - - -
Cash flows other operating - -1.08000M -2.84500M -0.66500M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 72.98M 80.75M 83.84M -
Change in working capital 2.81M 2.05M 0.93M -1.67900M 0.51M
Stock based compensation 33.23M 15.32M 3.27M 1.24M 0.79M
Other non cash items -0.69000M 1.49M 0.03M 0.07M -60.26900M
Free cash flow -153.54800M -116.27400M -40.92600M -25.11200M -11.67900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
KRYS
Krystal Biotech Inc		 5.97 1.98% 307.79 72.94 181.82 47.33 5.82 42.94 68.28
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech Inc

2100 Wharton Street, Pittsburgh, PA, United States, 15203

Key Executives

Name Title Year Born
Mr. Krish S. Krishnan M.B.A., M.S. Founder, Chairman, Pres & CEO 1965
Ms. Suma M. Krishnan Founder, COO, Pres of R&D and Director 1965
Ms. Kathryn A. Romano Exec. VP & Chief Accounting Officer 1981
Dr. Andreas C. Orth Exec. VP & Chief Commercial Officer 1970
Ms. Gloria Lin Accounting Mang. NA
Mr. Ram Kamineni Sr. VP of CMC & Technical Operations NA
Ms. Meg Dodge VP of Investor Relations & Corp. Communications NA
Mr. David Glynn Gen. Counsel, Commercial & Compliance NA
Mr. John Karakkal VP of North American Sales & Marketing NA
Ms. Katherine Tuminello HR & Office Mang. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions